A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women

OBJECTIVES: Primary objectives were to evaluate the safety and systemic pharmacokinetics (PK) of DARE-HRT1, an intravaginal ring (IVR), which releases 17β2-Estradiol (E2) with progesterone (P4) for 28 days in healthy postmenopausal women. METHODS: This was a randomized, open-label, 2-arm, parallel g...

Descripción completa

Detalles Bibliográficos
Autores principales: Thurman, Andrea, Hull, M. Louise, Stuckey, Bronwyn, Hatheway, Jessica, Zack, Nadene, Mauck, Christine, Friend, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389193/
https://www.ncbi.nlm.nih.gov/pubmed/37339390
http://dx.doi.org/10.1097/GME.0000000000002210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389193/
https://www.ncbi.nlm.nih.gov/pubmed/37339390
http://dx.doi.org/10.1097/GME.0000000000002210

Ejemplares similares